Savita Bisht

TL;DR: Nanocurcumin provides an opportunity to expand the clinical repertoire of this efficacious agent by enabling ready aqueous dispersion and demonstrating comparable in vitro therapeutic efficacy to free curcumin against a panel of human pancreatic cancer cell lines.

TL;DR: This review is intended to provide the reader an update on the bioavailability and pharmacokinetic pitfalls of free curcumin, and a comprehensive cataloging of ongoing approaches that have been undertaken to resolve these issues, with the goal of harnessing the true potential of this anti-cancer agent in the clinical arena.

TL;DR: In this paper, a doxorubicin-curcumin composite nanoparticle formulation called nanoDoxCurc (NDC) was proposed to overcome multidrug resistance (MDR) phenotype in cancer cells.

TL;DR: Evidence implicating aberrant Hippo signaling in ccRCC proliferation, invasiveness, and metastatic potential is provided and CYR61 and c-Myc as well as signaling through the endothelin axis are suggested as bona fide downstream effectors of YAP and establish aberrant hippo signaling as a potential therapeutic target inccRCC.

TL;DR: N nano-encapsulation of EF24 into pegylated liposomes (Lipo-EF24) and evaluation of these particles in preclinical in vitro and in vivo model systems of pancreatic cancer suggest that this drug might be a promising starting point for development of future combinatorial therapeutic regimens against Pancreatic cancer.